Bioelectronic medicine is starting to gain widespread attention after years of skepticism. That skepticism is now being eroded by a growing wave of peer-reviewed research overtaking the medical establishment with evidence of its efficacy, especially as an alternative to potentially dangerous drugs, including opioid-based painkillers responsible for the current epidemic of addiction and death by overdose.
The basic premise behind Bioelectronic medicine is to solve health issues by tapping into the body’s natural electrochemical operating system. On a very fundamental level, the body works by electricity – in every cell, throughout the nervous system, even at the molecular level.
Hence, with tuned modalities, electricity can be used to treat many health problems.
Here, we take a look at three interesting publicly traded stocks with strong ties to this emerging field, including Novocure Ltd (NASDAQ:NVCR), Electromedical Technologies Inc (OTCMKTS:EMED), and electroCore Inc (Nasdaq:ECOR).
Novocure Ltd (NASDAQ:NVCR) bills itself as an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and mesothelioma.
Novocure Ltd (NASDAQ:NVCR) just recently announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated period of significant innovation and growth and to recognize the proven senior management experience of key Novocure leaders.
According to the company’s release, after eight years of service as Chief Financial Officer, Wilco Groenhuysen has been appointed to an expanded Chief Operating Officer role responsible for the general and administrative management of the company. He will also assume responsibility for the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four Phase 3 clinical trials over the next few years.
Even with that news, the action hasn’t really heated up in the stock, with shares moving net sideways over the past week. Shares of the stock have powered higher over the past month, rallying roughly 5% in that time on strong overall action.
Novocure Ltd (NASDAQ:NVCR) generated sales of $115.9M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 13.8% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($347.5M against $85.1M).
Electromedical Technologies Inc (OTCMKTS:EMED) is a pure play in Bioelectronic medicine. The company has already had commercial success in that department, with a line of pain-curing products – the WellnessPro – already out gaining advocates including major universities and professional athletes in the NBA, NFL, and NHL.
Over 100 million Americans suffer from some form of chronic pain. Globally, experts believe the chronic pain market is an opportunity expected to grow to $69 – $105 billion over coming years. But current solutions to this epidemic are woefully inadequate. According to data from the National Institutes of Health (NIH), in 2018 over 128 people died each day from opioid-related drug overdose.
The company’s WellnessPRO-Plus device is a self-administration tool for bioelectronic medical treatment of chronic pain. EMED is also developing its next generation product, the WellnessPro® POD, which will address not only chronic pain, but new modalities using frequencies that naturally tap into the body’s electrochemical system without the use of potentially harmful drugs.
Electromedical Technologies Inc (OTCMKTS:EMED) just announced that the Financial Industry Regulatory Authority, Inc. has approved the Company’s official symbol change to “EMED” (from “ELCQ”). The stock began trading under the “EMED” symbol on September 4, 2020.
This follows a strong shareholder letter that discussed the company’s recent advances, including the establishment of a practitioner program in California, a collaborative agreement with Nazarbayev University, Nur-Sultan, Kazakhstan, to develop a comprehensive research program in defining the effects of electro-modulation on a physiological state of human body by studying the impacts of alternating electrical fields on cell signaling, and the recent awarding of a “COFEPRIS license” allowing the company to sell medical devices in Mexico.
And the stock has been acting well over recent days, up something like 4% in that time.
Electromedical Technologies Inc (OTCMKTS:EMED) has already sold 8,000 units of the WellnessPRO® device, with customers including over 250 schools and universities, who use these devices in their athletic departments and research programs, and a number of professional athletes and sports teams in the NBA, NHL, and NFL.
electroCore Inc (Nasdaq:ECOR) trumpets itself as a commercial stage medical device company that engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies.
The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
electroCore Inc (Nasdaq:ECOR) just announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,” by Wittbrodt, Bremner et. al. in the journal Brain Stimulation.
According to the release, the paper reports on a double-blind sham-controlled study of nineteen participants who had experienced trauma but did not have the diagnosis of PTSD and highlights the ability of nVNS to decrease the fear associated with emotional stress. The authors hypothesized that nVNS could mitigate the stress associated with traumatic triggers compared to a sham device based on its ability to decrease the level of neural activity in areas of the brain believed to be responsible for the negative reaction.
The stock has suffered a bit of late, with shares of ECOR taking a hit in recent action, down about -19% over the past week.
electroCore Inc (Nasdaq:ECOR) generated sales of $753K, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 2.6% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($18.9M against $5.1M).
COMPENSATION DISCLOSURE: Section 17(b) of the 1933 Act requires publishers to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b): Tiger Global Management Partners LLC has compensated a third party to produce and present weekly content for various companies for the publication. For more information, please click here. In addition, this article is part of JournalTranscript.com Networks. Read the JournalTranscript.com Networks Disclaimer.